Not Just Medicare, UnitedHealth's Optum Rx Gets Its Own DOJ Checkup

UnitedHealth Group faces heightened regulatory risk as the Department of Justice's criminal probe expands beyond Medicare Advantage to include its Optum Rx pharmacy benefit manager, which generated $5.8 billion in 2024 income, and physician reimbursement practices. This widening scrutiny, coupled with UnitedHealth's rising medical care ratio from 83.2% in 2023 to 87.1% in H1 2025 and similar cost pressures impacting peers, signals significant operational challenges. Consequently, UNH shares have declined 40.6% year-to-date, with 2025 earnings estimates cut by 41.4% to $16.21 per share, reflecting a challenging outlook.

Analysis

UnitedHealth Group is confronting a dual threat of escalating regulatory scrutiny and deteriorating operational fundamentals. The U.S. Department of Justice's criminal probe has expanded beyond Medicare Advantage to include the highly profitable Optum Rx division, which generated $5.8 billion in 2024 operating income, and physician reimbursement practices. This broadens the scope of legal and financial risk, targeting a key source of diversified earnings. Concurrently, the company is experiencing severe margin pressure, evidenced by its medical care ratio increasing from 83.2% in 2023 to an anticipated 87.1% in the first half of 2025. This trend is not isolated; peers like Centene and Elevance Health have also issued substantial downward revisions to their 2025 guidance due to rising medical costs. Despite its stock underperforming the industry year-to-date with a 40.6% loss, UNH trades at a forward P/E of 17.61, a premium to the industry average of 14.83. This valuation appears disconnected from the consensus estimate of a 41.4% drop in 2025 earnings per share to $16.21.

Key Decisions for Investors

• Investors should closely monitor the expanding DOJ investigation, as any adverse findings concerning the high-margin Optum Rx segment could materially impair a primary growth and profit driver for the company.
• Given the sharp rise in the medical care ratio and a projected 41.4% decline in 2025 EPS, the stock's premium valuation relative to its industry peers warrants significant caution and a re-evaluation of long positions.
• Consider the systemic nature of the cost pressures impacting the entire managed care sector, as demonstrated by peer guidance cuts, which suggests that near-term headwinds are unlikely to be company-specific or easily resolved.
• The Zacks Rank #5 (Strong Sell) and the deeply negative sentiment score of -0.8 reflect a strong consensus on the current risks, indicating that a contrarian bullish stance carries exceptionally high risk until there is a clear positive catalyst.